Watchmaker Genomics Advances TAPS Commercialization with Achievement of Key Technology Transfer Milestone [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
applications, today announced the successful completion of a key milestone under its TAPS (TET-assisted pyridine borane sequencing) Technology License and Supply Alliance with Exact Sciences. This progress underscores Watchmaker's commitment to commercializing TAPS, a transformative epigenetic analysis technology for high-accuracy genomic DNA methylation analysis, and accelerates efforts to bring TAPS-powered products to market, with early access programs launching soon and full commercial availability anticipated later in 2025. TAPS enables direct and high-fidelity methylation mapping with significantly reduced template damage and noise compared to conventional bisulfite sequencing, unlocking new possibilities for research and clinical applications, including liquid biopsy-based cancer detection and identification of novel epigenetic biomarkers. Unlike traditional methods, TAPS provides a positive readout by selectively converting methylated and hydroxymethylated cytosine into thym
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter [Seeking Alpha]Seeking Alpha
- Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS [Yahoo! Finance]Yahoo! Finance
- Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCSBusiness Wire
- Grail: Downgraded From Speculative Buy To Hold As The Stock Price Appreciated Faster Than Expected [Seeking Alpha]Seeking Alpha
- Exact Sciences (NASDAQ:EXAS) was given a new $105.00 price target on by analysts at Stifel Nicolaus.MarketBeat
EXAS
Earnings
- 11/3/25 - Beat
EXAS
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/26/25 - Form DEFA14A
- 11/24/25 - Form DEFA14A
- EXAS's page on the SEC website